{
  "id": "beb639c5c86a9b44",
  "title": "Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of\u00a0Zorevunersen, an Investigational Medicine\u00a0for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting",
  "description": "\u2014Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in seizure-free days, in addition to improvements in cognition, beh\u2026",
  "content": "Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs)demonstrate durable seizure reductions, including increases in seizur\u2026 [+23824 chars]",
  "source": "GlobeNewswire",
  "source_url": "https://www.globenewswire.com/news-release/2025/12/05/3200739/0/en/Biogen-and-Stoke-Therapeutics-Present-Data-that-Further-Support-the-Disease-Modifying-Potential-of-Zorevunersen-an-Investigational-Medicine-for-the-Treatment-of-Dravet-Syndrome-at-.html",
  "published_at": "2025-12-05T14:00:00Z",
  "fetched_at": "2025-12-06T18:33:06.472112+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "search:drug approval FDA breakthrough"
  ],
  "location": null,
  "raw_data": {
    "source": {
      "id": null,
      "name": "GlobeNewswire"
    },
    "author": "Biogen Inc.",
    "title": "Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of\u00a0Zorevunersen, an Investigational Medicine\u00a0for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting",
    "description": "\u2014Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in seizure-free days, in addition to improvements in cognition, beh\u2026",
    "url": "https://www.globenewswire.com/news-release/2025/12/05/3200739/0/en/Biogen-and-Stoke-Therapeutics-Present-Data-that-Further-Support-the-Disease-Modifying-Potential-of-Zorevunersen-an-Investigational-Medicine-for-the-Treatment-of-Dravet-Syndrome-at-.html",
    "urlToImage": "https://ml.globenewswire.com/Resource/Download/80f9c524-3da2-4583-a763-0dad931fa182",
    "publishedAt": "2025-12-05T14:00:00Z",
    "content": "Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs)demonstrate durable seizure reductions, including increases in seizur\u2026 [+23824 chars]"
  }
}